Market News & Trends
Biora Therapeutics Announces New Patent for its NaviCap Targeted Oral Delivery Platform
Biora Therapeutics, Inc. recently announced it received an Issue Notification from the US Patent and Trademark Office for a patent related to the treatment of…
Nectin Therapeutics Adds Combination Therapy Arm & Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent
Nectin Therapeutics Ltd. recently announced it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy arm with the immune-oncology drug…
Ethris Initiates First-in-Human Dosing in Phase 1 Study for the Treatment of Virus-Induced Asthma
Ethris GmbH recently announced the dosing of the first healthy participant in its first-in-human study of lead candidate ETH47, which was developed using Ethris’ Stabilized…
Successful Transfer of NDA Acknowledged by FDA From Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch
Emergex Vaccines Holding Limited recently announced the company has transferred ownership, as of May 2023, of the existing US FDA New Drug Application (NDA) of the investigational MAP originally intended….
Revive Therapeutics Collaborates With Attwill Medical Solutions for the Clinical & Commercial Development of a Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Ltd. recently announced it has signed a collaboration agreement with Attwill Medical Solutions LP (AMS) for the clinical and commercial development of the…
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Unicycive Therapeutics, Inc. recently announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC). OLC…
POINT Biopharma & Lantheus Announce Positive Topline Results From Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
POINT Biopharma Global Inc. and Lantheus Holdings, Inc. recently announced statistically significant topline results from the pivotal….
Global Confidence in Drug Delivery Innovation Remains at Record Highs According to Pharmapack
The annual Pharmapack Drug Delivery Innovation Index is released ahead of Europe’s premier drug delivery and packaging event, Pharmapack Europe 2024 (January 24-25) – held at the Paris Expo, Porte de Versailles (Hall 7.2). The results showed….
Asahi Kasei Develops Novel Membrane System to Dehydrate Organic Solvents Without Heat or Pressure - Contributing to Process Optimization in the Pharmaceutical Industry
Asahi Kasei has developed a novel membrane system for dehydrating organic solvents for pharmaceutical applications without the application of heat or pressure. This system can…
Roche Completes Acquisition of Telavant From Roivant, Including Rights to Novel TL1A Directed Antibody for Inflammatory Bowel Disease Treatment
Roivant recently announced the completion of the previously announced acquisition by Roche of Telavant, for an upfront payment of approximately $7.1 billion…..
Aeterna Zentaris & Ceapro Announce Merger to Create Diversified Biopharmaceutical Company
Aeterna Zentaris Inc. and Ceapro Inc. recently announced they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction…..
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
Rani Therapeutics Holdings, Inc. recently announced pharmacodynamic data of an incretin triagonist of the GLP-1, GIP, and glucagon receptors delivered transenterically, which mimics the RaniPill…
Aptamer Group Signs Material Agreement With Genetic Medicines Company
Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, recently announces it has entered into a material…
Clene Announces Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc. recently announced the publication of a peer-reviewed article describing brain target engagement by CNM-Au8, the…
ReciBioPharm Partners With Acuitas Therapeutics to Provide Rapid Technology Transfers & cGMP Manufacture of LNP Formulations
ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, and biotechnology firm Acuitas Therapeutics have recently announced they are taking their partnership to the next level….
Athira Pharma Announces Encouraging Results From SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia & Dementia With Lewy Bodies
Athira Pharma, Inc. recently announced findings from the exploratory SHAPE Phase 2 clinical trial to evaluate fosgonimeton (ATH-1017) in patients with Parkinson’s disease dementia and dementia…
ADMA Biologics Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age & Older
ADMA Biologics, Inc. recently announced the US FDA has approved the company’s supplemental Biologics License Application submitted under section 351(a) of the Public Health Service…
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Immuneering Corporation recently announced the US FDA has cleared its Investigational New Drug (IND) application for IMM-6-415, paving the way for the company to initiate…
Abzena Partners With ProteoNic to Offer Enhanced CHO Cell Line
Abzena, the leading end-to-end bioconjugate and complex biologics CDMO, recently announced a partnership with ProteoNic Biosciences BV to license their premium protein expression….
Coya Therapeutics & Dr. Reddy’s Laboratories Enter Development & Commercialization Agreement for ALS Treatment
Dr. Reddy’s Laboratories SA and Coya Therapeutics, Inc. recently announced they have entered into a development and license agreement for the development and commercialization of COYA 302, an investigational combination therapy for….
